Aoki Yuji, Kai Hisashi, Kajimoto Hidemi, Kudo Hiroshi, Takayama Narimasa, Yasuoka Suguru, Anegawa Takahiro, Iwamoto Yoshiko, Uchiwa Hiroki, Fukuda Kenji, Kage Masayoshi, Kato Seiya, Fukumoto Yoshihiro, Imaizumi Tsutomu
Department of Internal Medicine, Division of Cardio-Vascular Medicine, Kurume University School of Medicine.
Circ J. 2014;78(9):2284-91. doi: 10.1253/circj.cj-14-0027. Epub 2014 Jun 30.
It has been shown that increased short-term blood pressure (BP) variability (BPV) aggravates hypertensive cardiac remodeling in spontaneously hypertensive rats (SHRs) through a cardiac angiotensin II (angII) system. However, little was known about the renal damage induced by large BPV. Thus, histological changes in the kidney were investigated and candesartan, an angII type 1 receptor blocker (ARB), was also examined to see whether it would prevent renal damage in SHRs with large BPV. METHODS AND RESULTS: Bilateral sinoaortic denervation (SAD) was performed in SHRs to create a model of a combination of hypertension and large BPV. SAD increased BPV without changing mean BP. Seven weeks later, SAD induced patchy, wedge-shaped, focal sclerotic lesions accompanied by interstitial fibrosis and ischemic changes of glomeruli and tubules in the cortex. The pre-glomerular arterioles adjacent to the sclerotic lesions showed arteriolosclerotic changes associated with vascular smooth muscle cell proliferation and extracellular matrix deposition, leading to the luminal narrowing and occlusion. Chronic treatment with a subdepressor dose of candesartan prevented not only arteriolosclerotic changes but also cortical sclerotic lesions in SHRs with SAD without changing BPV.
Large BPV aggravates pre-glomerular arteriolosclerosis, which results in the cortical sclerotic changes in SHRs through a local angII-mediated mechanism. This study raised the possibility that ARB is useful for renal protection in patients who have a combination of hypertension and increased BPV.
研究表明,短期血压(BP)变异性(BPV)增加通过心脏血管紧张素II(angII)系统加重自发性高血压大鼠(SHR)的高血压心脏重塑。然而,关于大BPV所致肾损害知之甚少。因此,本研究调查了肾脏的组织学变化,并检测了血管紧张素II 1型受体阻滞剂(ARB)坎地沙坦,以观察其是否能预防大BPV的SHR的肾损害。
对SHR进行双侧去窦弓神经支配(SAD)以建立高血压合并大BPV的模型。SAD增加BPV但不改变平均血压。7周后,SAD诱导皮质出现片状、楔形、局灶性硬化性病变,伴有间质纤维化以及肾小球和肾小管的缺血性改变。与硬化性病变相邻的肾小球前小动脉显示出与血管平滑肌细胞增殖和细胞外基质沉积相关的小动脉硬化改变,导致管腔狭窄和闭塞。用亚降压剂量的坎地沙坦进行慢性治疗不仅可预防SAD的SHR的小动脉硬化改变,还可预防皮质硬化性病变,且不改变BPV。
大BPV加重肾小球前小动脉硬化,通过局部angII介导的机制导致SHR的皮质硬化改变。本研究提出了ARB对高血压合并BPV升高患者肾脏具有保护作用的可能性。